How US-UK drug deal will benefit patients | Letters
Many new medicines have reached NHS patients as a result of the government’s reformed pricing arrangements, writes Richard Torbett. Plus a letter from Nick HoileThe suggestion that the US-UK pharmaceutical agreement will result in excess deaths is alarmist and relies on a heavily